LC
DNLI icon

Lindbrook Capital’s Denali Therapeutics DNLI Stock Holding History

Lindbrook Capital’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$2.08K Sell
153
-102
-40% -$1.95K ﹤0.01% 2275
2024
Q4 		$5.2K Sell
255
-28
-10% -$717 ﹤0.01% 1971
2024
Q3 		$8.24K Buy
283
+58
+26% +$1.44K ﹤0.01% 1783
2024
Q2 		$5.22K Sell
225
-89
-28% -$1.71K ﹤0.01% 1970
2024
Q1 		$6.44K Sell
314
-332
-51% -$6.24K ﹤0.01% 1787
2023
Q4 		$13.9K Buy
646
+407
+170% +$8.06K ﹤0.01% 1366
2023
Q3 		$4.93K Sell
239
-403
-63% -$10.2K ﹤0.01% 1778
2023
Q2 		$18.9K Buy
642
+188
+41% +$5.29K ﹤0.01% 1124
2023
Q1 		$10.5K Buy
454
+99
+28% +$2.73K ﹤0.01% 1427
2022
Q4 		$9.87K Buy
355
+78
+28% +$2.32K ﹤0.01% 1436
2022
Q3 		$9K Buy
277
+54
+24% +$1.76K ﹤0.01% 1363
2022
Q2 		$7K Buy
223
+19
+9% +$498 ﹤0.01% 1396
2022
Q1 		$7K Sell
204
-407
-67% -$14K ﹤0.01% 1438
2021
Q4 		$27K Buy
+611
New +$28.9K ﹤0.01% 914
2021
Q2 		– Sell
-34
Closed -$2K – 1929
2021
Q1 		$2K Buy
+34
New +$2.28K ﹤0.01% 1535

Other funds holding DNLI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Lindbrook Capital's DNLI Position: Q1 2025 in Review

Lindbrook Capital reduced its Denali Therapeutics (DNLI) stake by 40% in Q1 2025, selling an estimated $1.95K and leaving 153 shares worth $2.08K. The position accounts for ﹤0.01% of the portfolio, ranked #2275.

Lindbrook Capital first reported a position in DNLI in Q1 2021 and has held it in 15 quarters since. The position peaked at $27K in Q4 2021. 222 funds tracked by Wall St. Rank hold DNLI as of Q1 2025.

  • Lindbrook Capital held 153 shares of Denali Therapeutics worth $2.08K as of Q1 2025.
  • Lindbrook Capital sold 102 Denali Therapeutics shares in Q1 2025, an estimated $1.95K.
  • Denali Therapeutics made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #2275 holding.
  • Lindbrook Capital first reported a position in Denali Therapeutics in Q1 2021 and has held it in 15 quarters since.
  • Lindbrook Capital's Denali Therapeutics position peaked at $27K in Q4 2021.
  • 222 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.